FDCBeyond's analysis on FDC2026-07-23 — Ascletis claims its oral ASC36_35 FDC outperforms eloralintide/tirzepatide combo in preclinical obesity model, positioning it as a potential next‑generation weight‑loss therapyRecent news mentioning FDC2026-08-10 — Ascletis Announces Initiation of Two Phase I Studies in U.S. for the Treatment of Obesity: ASC36 Once-Monthly Injection, an Amylin Receptor Peptide Agonist, and ASC36_35FDC Once-Monthly Injection, a Co-Formulation of ASC36 and GLP-1R/GIPR Peptide Agonist ASC35Browse the full archive →